{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-009272","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2022-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.612110+00:00","generated_at":"2026-06-27T13:26:19.823336+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Fennec Pharmaceuticals CCO Shubh Goel resigns; effective late February","bullets":["Shubh Goel, chief commercial officer, tendered resignation on Jan 31, 2022.","Goel will depart in late February 2022.","CEO Rosty Raykov thanked Goel for contributions; company continues launch preparations for PEDMARK.","PEDMARK is a treatment for cisplatin-induced ototoxicity in pediatric patients, pending approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-009272","json":"https://secwatch.observer/filing/0001104659-22-009272.json","markdown":"https://secwatch.observer/filing/0001104659-22-009272.md","text":"https://secwatch.observer/filing/0001104659-22-009272.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000110465922009272/0001104659-22-009272-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000110465922009272/tm224898d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T13:26:19.823336+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b7d6b2cc3","claim":"Shubh Goel resigned as Chief Commercial Officer at FENNEC PHARMACEUTICALS INC..","evidence_excerpt":"On January 31, 2022 Fennec Pharmaceuticals Inc. announced the resignation of Chief Commercial Officer, Shubh Goel.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465922009272/0001104659-22-009272-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}